Login to Your Account



HISTORY REPEATS ITSELF, SIX MONTHS LATER

GSK’s phase III cancer vaccine miss in NSCLC is double trouble for Agenus

By Marie Powers
Staff Writer

Friday, March 21, 2014
History repeated itself for Agenus Inc. six months after Glaxosmithkline plc’s (GSK) phase III DERMA trial of its MAGE-A3 cancer immunotherapeutic, formulated with Agenus’ QS-21 Stimulon adjuvant, missed its primary endpoint of extending disease-free survival (DFS) in melanoma. This time, the culprit was non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription